Search the Newsreel

AEXA|American Exceptionalism Acquisition Ord Shs Class A|Price:11.580|Chg%:-0.030

This article provides a comprehensive overview of American Exceptionalism Acquisition Ord Shs Class A (AEXA), detailing its current stock price, key financial figures, and recent performance. It includes technical indicators and moving averages, offering insights into potential market trends. The report also lists major …

ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055

Zentalis Pharmaceuticals Inc. (ZNTL) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancers, specifically azenosertib, a WEE1 inhibitor. Despite a strong stock market performance over the past month, the company's fundamentals and technicals are considered weak, with a "Buy" rating …

Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis

Oppenheimer initiated coverage on Palisade Bio (NASDAQ: PALI) with a Buy rating, highlighting its potential in the inflammatory bowel disease market. The company's lead drug, PALI-2108, a once-daily oral PDE4 inhibitor, is seen as a strong candidate for ulcerative colitis and Crohn's disease due …

Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ)

Oppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating and an $8 price target, representing a 321% upside. This initiation caused the stock to jump approximately 14% in morning trading. Analyst Leland Gershell views strong potential in the company's PALI-2108.

Rodman & Renshaw initiates Zentalis stock with buy on drug potential

Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a buy rating and an $11.00 price target, citing the commercial potential of azenosertib, an investigational WEE1 inhibitor for platinum-resistant ovarian cancer. The firm believes the drug could receive accelerated approval if the DENALI …

Materialise (MTLS) Q1 2026 earnings summary

Materialise (MTLS) reported Q1 2026 earnings with stable revenue of EUR 66.3 million year-over-year, despite currency headwinds. The company's strategic divestments of QuickFit and Eyewear businesses led to a sharpened focus on core activities, alongside an expansion in its medical portfolio and a deepened …

PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform'

Oppenheimer has initiated coverage on Palisade Bio (PALI) with an 'Outperform' rating and a price target of $8.00, suggesting significant upside from its current price of $1.90. Despite a low GF Score™ of 35/100 due to profitability challenges typical for a clinical-stage biotech, the …

Materialise Updates Ongoing Share Buyback Program After Repurchasing 51,168 Shares

Materialise (MTLS) has provided an update on its ongoing share buyback program. Between July 13 and July 17, 2026, the company repurchased 51,168 shares on Nasdaq at an average price of EUR 5.84 per share. Since the program's inception on January 26, 2026, Materialise …

Medalist Diversified (Nasdaq: MDRR) plans Texas Caliber Collision acquisitions via DSTs

What's Going On With Inovalis Real Estate Investment Trust Stock Wednesday?

Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward (MTLS)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)

Monteverde & Associates PC, a class action firm, has launched an investigation into the sale of Personalis, Inc. (NASDAQ: PSNL) to Tempus AI, Inc. The firm is examining whether the proposed transaction, which offers Personalis shareholders $16.25 per share, is a fair deal. Shareholders …

Tempus AI and Personalis (NASDAQ: PSNL) detail merger risks and upcoming SEC filings

Tempus AI is set to acquire Personalis, Inc., with both companies detailing the associated merger risks and upcoming SEC filings in a Form 425 document. Key risks include failure to secure stockholder or regulatory approvals, potential litigation, integration challenges, and a termination clause allowing …

Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL)

Personalis (PSNL) achieved commercial success through increased clinical adoption, Medicare reimbursement expansion, and a strong MRD platform. However, the all-stock acquisition by Tempus AI at a 6% premium transforms PSNL from an independent growth story to one dependent on Tempus's share price. Despite operational …

Personalis to be acquired by Tempus AI in merger

Australis Oil & Gas (ASX:ATS) Advances 5.00% as Colorado Operations and Production Strategy Remain in Focus

Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion

Tempus AI has announced its acquisition of Personalis, a cancer-monitoring firm, for $1.5 billion in an all-stock deal. The acquisition focuses on Personalis' NeXT Personal test, which uses minimal residual disease technology to detect circulating tumor DNA, a market estimated to be worth $20 …

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus AI, Inc. is set to acquire Personalis, Inc. for $1.5 billion, integrating Personalis' molecular residual disease (MRD) technology into Tempus' AI-enabled precision oncology platform. This acquisition aims to enhance cancer monitoring, biomarker discovery, and personalized cancer care by combining Personalis' industry-leading MRD tests …

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Tempus AI, a healthcare technology company, is acquiring cancer testing company Personalis for $1.5 billion. This acquisition led to a significant drop in the stock prices of both companies on Monday. Tempus AI's shares are already down 18% this year.

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI (TEM) announced its intention to acquire cancer diagnostics company Personalis (PSNL) for $1.5 billion, leading to a decline in shares for both medtech companies. This acquisition follows earlier rumors of interest from Merck and potentially Tempus AI in Personalis, which develops a …

MATERIALISE NV 6-K — Jul 20, 2026

This document is a 6-K filing by Materialise NV dated July 20, 2026. It is a current report accessible on SEC.gov, with the source document served from SEC EDGAR. The platform also promotes a research report titled "The Power Delivery Gap."

Tempus AI Announces Merger Agreement to Acquire Personalis

Tempus AI, Inc. has announced a definitive merger agreement to acquire genomics company Personalis, Inc. in a two-step merger. The deal, approved by both boards, will involve Personalis shareholders receiving Tempus Class A stock with an option for cash consideration. The acquisition aims to …

Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis

Latham & Watkins LLP advised Tempus AI on its US$1.5 billion acquisition of Personalis, Inc. This acquisition will expand Tempus AI's capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis to monitoring. The Latham & Watkins team was …

Materialise (Nasdaq: MTLS) details July repurchases in €30m buyback

Materialise NV has provided an update on its €30 million share buyback program, detailing repurchases made between July 13 and July 17, 2026. During this period, the company bought back 51,168 shares on the Nasdaq at an average price of €5.84 per share, totaling …

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Tempus AI, Inc. is set to acquire Personalis, Inc. for $1.5 billion, integrating Personalis' NeXT Personal® tumor-informed minimal residual disease (MRD) liquid biopsy test into Tempus' AI-enabled clinical data engine. This acquisition targets a $20 billion market and aims to transform cancer patient monitoring …

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

Zentalis Pharmaceuticals (ZNTL) shares have surged 28% in the past three months, largely due to investor confidence in its lead oncology candidate, azenosertib, a WEE1 inhibitor targeting ovarian cancer and other tumor types. The company is advancing azenosertib through pivotal trials for platinum-resistant ovarian …

Tempus to Buy Cancer-Tech Firm Personalis for $1.7 Billion

Tempus AI Inc., an artificial intelligence company focused on disease prevention and treatment, has announced its agreement to acquire Personalis Inc., a cancer-testing company. The deal values Personalis at an equity valuation of $1.7 billion, with Tempus paying its shareholders $16.25 per share, totaling …

Tempus to buy cancer test maker Personalis for $1.5 billion

Tempus AI announced its acquisition of Personalis for approximately $1.5 billion, enhancing its oncology portfolio with Personalis' NeXT personal cancer test. The deal, primarily stock-based, led to a drop in shares for both companies due to investor skepticism regarding Tempus' potential upside. The acquisition …

Tempus to buy cancer-tech firm Personalis for $1.7B

Tempus, a company specializing in cancer technology, has announced its intention to acquire Personalis for $1.7 billion. This acquisition is expected to expand Tempus's capabilities in the health care sector. The deal was reported by Bloomberg.

Should I buy Zentalis Pharmaceuticals (ZNTL)

ZNTL Jumps As Mizuho Targets Upside On Cancer Drug

Zentalis Pharmaceuticals Inc. (ZNTL) saw its stock jump by over 10% after Mizuho initiated coverage with an "Outperform" rating and an $8 price target, citing attractive risk-reward for its cancer drug azenosertib. The stock's surge was driven by expectations of key Phase 2 data …

MTLS Stock Price and Chart — NASDAQ:MTLS

This page provides a comprehensive overview of Materialise NV (MTLS) stock, including its current price, historical performance data, key financial metrics, and company profile. It also features a collection of trading ideas and analyses from various users, along with technical indicators, analyst ratings, and …

Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Mizuho Securities has initiated a "Buy" rating for Zentalis Pharmaceuticals (ZNTL) with an $8.00 price target, based on analyst Graig Suvannavejh's assessment. Suvannavejh, known for a 21.5% average return on recommended stocks, covers the Healthcare sector. The broader analyst consensus for Zentalis Pharmaceuticals is …

GoodVision AI Japan expansion tied to Calisa Acquisition (ALIS) merger plans

Calisa Acquisition Corp (ALIS) announced that its proposed merger partner, GoodVision AI Inc., revealed the establishment of its first next-generation AI Factory in Japan on July 16, 2026. This communication is made in the context of their Business Combination Agreement, with cautionary notes emphasizing …

Q4 2025 Personalis Inc Earnings Call Transcript

Personalis Inc. (PSNL) achieved significant clinical growth in Q4 2025, with a 329% year-over-year increase in clinical tests delivered and secured two Medicare coverage decisions for breast and lung cancer, validating their MRD technology. Despite a planned decline in legacy contract revenue and compressed …

Calisa Acquisition (NASDAQ: ALIS) backs 100 MW GoodVision AI factory plan in Japan

Calisa Acquisition Corp. (NASDAQ: ALIS) announced support for its proposed business combination partner, GoodVision AI, in its plan to develop a 100 MW AI Factory network in Japan through a strategic cooperation with AI Storm Co., Ltd. The initiative will begin with a 2 …